Neoadjuvant chemotherapy is a treatment routinely prescribed to patients diagnosed with muscle-invasive bladder cancer. Unfortunately, not all patients are responsive to this treatment and would greatly benefit from an accurate prediction of their expected response to c... View more
J. S. Chang, P. N. Lara, and C. X. Pan, “ Progress in personalizing chemotherapy for bladder cancer,” Adv. Urol., vol. 2012, 2012.
Wood, D. Raghavan, and E. D. Crawford, “ Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.,” N. Engl. J. Med., vol. 349, pp.
G. Griffiths, “ International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: Long-term results of the BA06 30894 trial,” J. Clin. Oncol., vol. 29, no. 16, pp. 2171-2177, 2011.
Quiroga, S. Benlloch, L. Ibarz, and R. Rosell, “ BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer,” Ann. Oncol., vol. 22, no. July 2010, pp. 139-144, 2011.
B. Kiss, M. D, V. Skuginna, M. D, A. Fleischmann, M. D, R. H. Bell, C. Collins, D. Ph, G. N. Thalmann, M. D, R. Seiler, and M. D, “ BclFig 5: A) Neural Network Training (dashed blue) and Test Error (solid green) over 300 epochs on microarray data. B) Same network applied to random data for comparison.